Reunion Neuroscience Schedules Fiscal Second Quarter 2023 Conference Call for Monday, November 14, 2022, at 8:30 A.M. ET
07 November 2022 - 11:30PM
Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or
the “Company”), a biopharmaceutical company committed to developing
innovative therapeutic solutions for underserved mental health
conditions, announced today that it plans to release its business
update and financial results for its fiscal 2023 second quarter
ended September 30, 2022, before market open on Monday, November
14, 2022.
The Company will
conduct a conference call and webcast to discuss its results that
morning, Monday, November 14, 2022, at 8:30 a.m. ET. To access the
call, please dial 1-877-407-9716 (within the U.S.) or
1-201-493-6779 (outside the U.S.) and provide conference ID
13734045. A live webcast of the conference call can be accessed via
the Events and Presentations section of the Reunion Investor
Relations website here.
For those unable to
attend the live call, a telephonic replay will be available until
11:59 p.m. ET on Monday, November 21, 2022. To access the replay
dial 1-844-512-2921 (within the U.S.) or 1-412-317-6671 (outside
the U.S.) and provide conference ID 13734045. The webcast will be
archived and available in the Events and Presentations section of
the Reunion Investor Relations website approximately one hour after
the conclusion of the live call.
About Reunion
Neuroscience Inc.
Reunion (formerly,
Field Trip Health Ltd.) is committed to developing innovative
therapeutic solutions for mental health conditions. The Company’s
lead asset, RE104, is a proprietary, novel serotonergic psychedelic
compound being developed as a potential fast-acting and durable
antidepressant for patients suffering from postpartum depression
and other mental health conditions. The U.S. Patent and Trademark
Office has granted the Company a patent for the claims related to
RE104, granting it exclusive rights to the composition of matter,
use and manufacturing of a family of hemi-ester compounds of
hydroxytryptamines, including RE104. The patent will provide
protection until 2041. Reunion is also developing the RE200 series,
which includes compounds with potential for more selective
serotonin receptor activity with reduced psychoactivity for
potential use in more chronic treatment paradigms and
indications.
Learn more at
https://www.investors.reunionneuro.com, and
https://www.reunionneuro.com.
Follow us on LinkedIn,
Twitter and Instagram.
To be added to the
Reunion Neuroscience email list, please email Reunion@kcsa.com with
“REUN” in the subject line.
Cautionary
Note Regarding Forward-Looking Information
This release includes
forward-looking information (within the meaning of Canadian
securities laws and within the meaning of the United States Private
Securities Litigation Reform Act of 1995) regarding the Company and
its business. Often but not always, forward-looking information can
be identified by the use of words such as "expect", "intends",
"anticipated", "believes" or variations (including negative
variations) of such words and phrases, or state that certain
actions, events or results "may", "could", "would" or "will" be
taken, occur or be achieved. Such statements are based on the
current expectations and views of future events of the management
of the Company and are based on assumptions and subject to risks
and uncertainties. Although the management of believes that the
assumptions underlying these statements are reasonable, they may
prove to be incorrect. The forward-looking events and circumstances
discussed in this release may not occur and could differ materially
as a result of known and unknown risk factors and uncertainties
affecting the companies. Although the Company has attempted to
identify important factors that could cause actual actions, events
or results to differ materially from those described in
forward-looking statements, there may be other factors that cause
actions, events or results to differ from those anticipated,
estimated or intended. Accordingly, readers should not place undue
reliance on any forward-looking statements or information. No
forward-looking statement can be guaranteed. Except as required by
applicable securities laws, forward-looking statements speak only
as of the date on which they are made and the Company does not
undertake any obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events, or otherwise. Additional information relating to the
Company can be located in its continuous disclosure documents on
the SEDAR website at www.sedar.com and on the EDGAR section of the
SEC’s website at www.sec.gov.
Neither Toronto Stock
Exchange, or its Regulation Services Provider, have approved the
contents of this release or accept responsibility for the adequacy
or accuracy of this release.
Media Contact:Shana
Marino KCSA Strategic Communications(347)
487-6189reunion@kcsa.com
Investor
Contacts:Phil Carlson / Sophia BashfordKCSA Strategic
Communications(646) 573-0776 / (929) 246-7307reunion@kcsa.com
Reunion Neuroscience (TSX:REUN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Reunion Neuroscience (TSX:REUN)
Historical Stock Chart
From Dec 2023 to Dec 2024